Alphamab Oncology presents Phase I ASCO data for JSKN016 in HER2-negative metastatic breast cancer

• Alphamab Oncology reported Phase I results for JSKN016 in HER2-negative advanced breast cancer, already presented at the 2026 ASCO Annual Meeting.
• The study showed meaningful tumor shrinkage in both triple-negative and hormone receptor-positive disease, supporting continued late-line development.
• Safety was described as manageable, with no treatment-related deaths reported and no interstitial lung disease observed in the trial.
• The recommended Phase II dose was set, clearing the path for multiple Phase II programs and an ongoing Phase III study in triple-negative breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260602-12182685), on June 02, 2026, and is solely responsible for the information contained therein.